Everyone should have access to medicines they can trust.

Meds We Can Trust Coalition


Artboard 4_patterns.png

260+ coalition members

including civil society organizations, philanthropic foundations, government entities and private partners from across 15 countries

teal line_bkgds2.png

Some of our partners

orange line_bkgds.png

Campaign Steering Committee

The campaign is overseen by a Steering Committee representing a diversity of geographies, issue area expertise and backgrounds. The Steering Committee guides the direction of the campaign, including annual planning and implementation of activities, and represents the campaign and coalition at events and in the media.


Katherine Bond, Vice President, International Regulatory Affairs, USP

Katherine Bond, Sc.D., is Vice President of International Regulatory Affairs for USP. She develops and executes USP’s global regulatory affairs agenda in alignment with strategic organizational objectives, and plays a key role in building and sustaining relationships with regulatory agencies and pharmacopeias around the world.

Dr. Bond brings more than twenty years of demonstrated public health leadership experience—in the field and in management—to her role at USP. Dr. Bond arrives at USP from the United States Food and Drug Administration, where she served in the Office of International Programs as Associate Director of Technical Cooperation and Capacity Building before being named Director of the Office of Strategy, Partnerships, and Analytics. Prior to public service, Dr. Bond focused her energies on priority public health issues such as infectious diseases and health systems impacting Southeast Asia and Africa.


Marie Lamy, Director, Access & Policy, Asia Pacific Leaders Malaria Alliance

With a keen interest in global health policy, health diplomacy and access to quality medicines, Marie brings specialised knowledge on regulatory systems strengthening to improve health security. Marie holds a PhD in Public Health Policy from the London school of Hygiene and Tropical Medicine. Prior to joining APLMA, she worked as a consultant on a project for regulatory systems profiling in the Greater Mekong Subregion. Marie previously worked as a project manager for i+solutions, an international not-for-profit consultancy organisation on supply chain management and as a Research Associate on global health governance, with a specific focus on Southeast Asia.


Mirfin Mpundu, Executive Director, Ecumenical Pharmaceutical Network/ReAct Africa

Mirfin Mpundu is the executive director of the Ecumenical Pharmaceutical Network (EPN) and the head of ReAct Africa and parts of ReAct’s global leadership team. He is a registered pharmacist in the U.S. and public health specialist with more than 20-years experience in pharmaceutical systems, supply chain management, pooled procurement and procurement contract management. His experience also includes achievement in consultancy and technical assistance provision in procurement and health product supply; quality assurance management for African health systems; and global-level experience and achievement in leadership in public health procurement, supply system practice, capacity building and skills transfer. He is a frequent participant and presenter on current pharmaceutical global issues, including AMR, non-communicable diseases and supply chain management. His regional and global efforts include promoting access and rational use of medicines, supporting EPN members on setting up antimicrobial stewardship programs and supporting countries setting up national action plans on AMR. He is passionate about strengthening pharmaceutical systems in developing countries. He holds a master’s degree in public health, an MBA and a degree in pharmacy.


Paul Newton, Director/Head, Oxford University & Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit; Medicine Quality Group, Worldwide Antimalarial Resistance Network (WWARN)

Paul Newton was appointed head of the Worldwide Antimalarial Research Network Antimalarial Quality Group in 2010. He is based at the Lao-Oxford-Mahosot Wellcome Trust Research Unit in the Microbiology Laboratory of Mahosot Hospital in Vientiane, Laos. After junior doctor training in infectious disease and internal medicine in the UK, he worked in the Mahidol Oxford Research Unit in Bangkok on malaria and melioidosis for four years before moving to Laos.


Sonja Potenze, Policy Manager, International Alliance of Patients’ Organizations (IAPO)

Sonja Potenze is IAPO’s Policy Manager having joined IAPO April 2019 after working in policy and campaigns roles at several health, membership and environmental organisations. She has for example played a part in the team that delivered the UK’s first ever National Clean Air Day campaign with Global Action Plan, provided policy research for the General Optical Council and assisted in the administration of the National Maternity and Perinatal Audit at the Royal College of Obstetricians and Gynaecologists. In addition, she has extensive experience in project and event management. 

Before moving to the UK in 2014 she worked for over 10 years as a freelancer in the media and film industries: as a journalist for the press and radio, in a variety of roles in different film and tv productions and in international film promotion. She holds an MA in Environment, Politics and Globalisation from King’s College London and a BA in Audiovisual Communication at Helsinki Metropolia University of Applied Sciences. In her personal life, she has been involved in the work of various human rights, women’s rights and environmental organisations, and has special interests including women’s access to safe healthcare, the history of medicine and herbal remedies.


Fiona Theunissen, Program Manager, Maternal Health, Concept Foundation

Fiona Theunissen is leading the advocacy and communications activities on a multi-country maternal health project which aims to reduce maternal deaths from postpartum haemorrhage.  Working with the WHO, MSD for Mothers and Ferring Pharmaceuticals, Concept Foundation is working to ensure affordable, quality manufacturing and supply of heat-stable carbetocin, an alternative to existing uterotonics for the prevention of PPH, for low- and middle-income countries.

Fiona has an extensive program management, advocacy, communications and technology transfer background in the health sector working with governments, civil society and the private sector to expand access to treatment for multidrug-resistant tuberculosis (MDR-TB) in India, China, Russia and South Africa, providing services for cancer patients and contributing to the expansion of midwifery services in low income countries.

Fiona holds an MBA in International Organizations from the University of Geneva and is the mother of two young children.


Brenda Waning, Chief of the Global Drug Facility, Stop TB Partnership

Brenda Waning is the Chief of the Global Drug Facility at the Stop TB Partnership and is an expert in developing, implementing, and analyzing pharmaceutical policies and market approaches to improve access to medicines and diagnostics in resource-limited settings. She most recently served as Coordinator of Market Dynamics at UNITAID, a WHO partnership based in Geneva. There, she lead UNITAID’s technical team responsible for monitoring trends in HIV/AIDS, TB, and malaria markets; identifying strategic opportunities to intervene in these markets; and assessing the public health and market impact of UNITAID’s interventions. Prior to joining UNITAID, she served as Director of Pharmaceutical Policy at Boston University School of Medicine, where she authored numerous peer-reviewed studies on pharmaceutical policy at local, national, and global levels. She serves on many expert advisory groups, including the Market Dynamics Advisory Group of the Global Fund and the Access and Delivery Advisory Committee of the Medicines for Malaria Venture.

teal line_bkgds2.png

Evidence Curation Working Group

Through the Evidence Curation Working Group, the Medicines We Can Trust Campaign aims to create a centralized hub of reliable research on the prevalence and impact of poor-quality medicines, identify opportunities to strengthen the case for the importance of prioritizing medicines quality and recognize expert voices advocating for medicines quality.


Dr. Veronika Wirtz, Boston University

Prof Veronika J. Wirtz, MSc, PhD is an Associate Professor in the Department of Global Health at the Boston University School of Public Health, where she is also Director of the World Health Organization Collaborating Center in Pharmaceutical Policy. She is a Visiting Professor of the National Institute of Public Health (INSP), Mexico, where she was a faculty member from 2005-2012.


Mirfin Mpundu, Executive Director, Ecumenical Pharmaceutical Network/ReAct Africa

Dr. Mirfin Mpundu is the Executive Director of the Ecumenical Pharmaceutical Network, an international NGO that supports church-run health institutions on pharmaceutical systems strengthening, promoting just and compassionate pharmaceutical services. A clinical pharmacist and public health specialist with 20+ years of proven experience in public health, pharmaceutical supply chain management, clinical, and regulatory pharmacy practice.


Dr. Paul Newton, University of Oxford

Prof Paul Newton is an infectious disease doctor, from the University of Oxford, in the Lao-Oxford-Mahosot-Wellcome Trust Research Unit in Vientiane Laos, within the MORU Tropical Health Network. He is head of the Medicine Quality Scientific Group of the Infectious Diseases Data Observatory.


Jude Nwokike

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.


Dr. Sachiko Ozawa, University of North Carolina at Chapel Hill

Sachiko Ozawa is an Associate Professor at the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. She is a health economist whose work focuses on generating evidence to improve access to vaccines and quality medicines. Her research focuses on the value of vaccines, and the economic impact of substandard and falsified medicines and antimicrobial resistance.


Dr. Raffaella Ravinetto, Senior Researcher, ITM

Dr. Raffaella Ravinetto, Pharm D, PhD, is a senior researcher at the Institute of Tropical Medicine (ITM) in Antwerp, where she manages a portfolio of research, networking and advocacy on medicines in low- and middle-income countries. She is the chairperson of the ITM Institutional Review Board and of the Ethics Review Board of Médecins Sans Frontières, and a scientific advisor to QUAMED.



local global.png

Our coalition has grown to over 260 partners across 15 countries.